Hopp til hovedinnhold

Prostataspesifikt antigen, PSA

Sist revidert:
Sist revidert av:
  1. Ødum L, et al. Prostataspecifikt antigen (PSA). Lægehåndbogen, sist oppdatert 09.01.2020.
  2. Metodebok.no. PSA, P. Nasjonal brukerhåndbok i Medisinsk Biokjemi, sist oppdatert 30.11.2021. metodebok.no  
  3. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46. New England Journal of Medicine  
  4. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2013; 1: CD004720. doi: 10.1002/14651858.CD004720.pub3. DOI  
  5. Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519. Published 2018 Sep 5. PMID: 30185521 PubMed  
  6. Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021 published online ahead of print, 2021 Aug 15. Eur Urol. 2021;S0302-2838(21)01927-8. PMID: 34407909 PubMed  
  7. Jiandani D, Randhawa A, Brown RE, et al. The effect of bicycling on PSA levels: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2015: 18: 208-12. PMID: 25939515 PubMed  
  8. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels. An evaluation of year-to-year fluctuations. JAMA 2003; 289: 2695-2700. Journal of the American Medical Association  
  9. Ito K, Yamamoto T, Ohi M, et al. Free/totaL PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4,1 to 10,0 ng/mL. Urology 2003; 61: 760-4. PubMed  
  10. Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol 2005; 12: 44-8. PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim

Tidligere fagmedarbeidere

  • Geir Thue, spesialist i alllmennmedisin, dr. med. NOKLUS og Oasen Legesenter, Bergen
  • Sverre Sandberg, overlege ved Nasjonalt kompetansesenter for porfyrisykdommer, Laboratorium for klinisk biokjemi, Haukeland Sykehus og professor i allmennmedisin, Seksjon for allmennmedisin, Universitetet i Bergen
  • Lars Ødum, led. overlæge, dr. med., Klinisk biokemisk afdeling, Roskilde Sygehus (Lægehåndbogen)